Drug Trial Radar · NCT01600079
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,505,647
Actual
Start
May 15, 2012
Primary completion
Oct 16, 2020
Study completion Oct 16, 2020
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Kaiser Permanente
- First posted
- May 16, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared to a cohort of unvaccinated participants.
Conditions
- Herpes Zoster
- Shingles
Interventions
ZOSTAVAX™Biological
ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts, Overall, and by Age (50-59, 60-69, 70-79 ≥80) at VaccinationTime frame: 10 years
- Incidence of Herpes Zoster in Vaccinated and Unvaccinated Cohorts by Time since VaccinationTime frame: 10 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.